Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Larsson Rolf) srt2:(2005-2009)"

Sökning: WFRF:(Larsson Rolf) > (2005-2009)

Sortera/gruppera träfflistan
  • Christensen, Kjeld, et al. (författare)
  • Effects on blood compatibility in vitro by combining a direct P2Y(12) receptor inhibitor and heparin coating of stents
  • 2006
  • Ingår i: Platelets. - 0953-7104. ; 17:5, s. 318-327
  • Tidskriftsartikel (refereegranskat)abstract
    • The effect of the direct platelet P2Y12 receptor inhibitor, AR-C69931MX, on activation of blood induced by stents with and without heparin coating was investigated using a whole blood Chandler loop model in vitro . Stents were deployed in Chandler loops. Fresh human blood with heparin and AR-C69931MX was rotated for 1 h at 37°C and used for measurements of platelets, microparticles, thrombin-antithrombin complex (TAT), fibrinogen binding to platelets, P-selectin expression by platelets, CD11b, Prothrombin Fragment F1+2, FXIa-AT, FXIIa-AT, C3a, sC5b-9 and stent score. In the first experiment there were four study groups with unmodified stents: 1a, no AR-C69931MX; 1b, 250 nmol/L; 1c, 750 nmol/L; 1d, 2250 nmol/L of AR-C69931MX. In the second experiment the concentration of AR-C69931MX was 500 nmol/L: 2a; tubings without stent; 2b; tubings with heparin-coated stent; 2c; tubings with unmodified stents. Heparin-coated stents were used in the third experiment: 3a; no AR-C69931MX; 3b; 500 nmol/L of AR-C69931MX. In the first experiment there were significant differences in all parameters analysed except for C3a, and stent score when the group with no AR-C69931MX was compared to all the groups with AR-C69931MX. In the second experiment there were significant differences in platelet count, TAT, FXIa-AT, FXIIa-AT and stent score when unmodified stents were compared to loops with no stents and partly to loops with heparin-coated stents. In the third experiment there was a significant reduction in generation of TAT, stent score and better preservation of platelet number by combining the platelet inhibitor and heparin-coated stents as compared to heparin-coated stents alone. The conclusion is that the direct P2Y12 receptor inhibitor AR-C69931MX reduced the different aspects of activation of blood induced by both unmodified and heparin-coated stents.
  • Larsson, Dhana E., et al. (författare)
  • Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines
  • 2009
  • Ingår i: Cancer Chemotherapy and Pharmacology. - 0344-5704. ; 65:1, s. 5-12
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE: There is a large need for better pharmacological treatment of neuroendocrine tumors. The aim of this study was to investigate and quantify the cytotoxic potentiating effects resulting from a combination of five substances, NSC 95397, emetine, CGP-74514A hydrochloride, Brefeldin A and sanguinarine chloride, chosen from a previous screening of 1,280 pharmacologically active agents on neuroendocrine tumor cells, with standard cytotoxic agents currently used in the treatment of neuroendocrine tumors.METHOD:The human pancreatic carcinoid cell line BON-1, human typical bronchial carcinoid cell line NCI-H727 and the human atypical bronchial carcinoid cell line NCI-H720 were used. Combinations between doxorubicin, etoposide, oxaliplatin, docetaxel, and each one of the five agents were studied and simultaneous exposures were explored using the median-effect method.RESULTS:Most of the combinations of NSC-95397 and emetine with doxorubicin, etoposide, docetaxel, and oxaliplatin showed synergism, and their remaining combinations were additive. Almost all of the CGP-74514A hydrochloride interactions were additive, while brefeldin A and sanguinarine displayed less synergy but more additive and antagonistic interactions in combination with the standard drugs.CONCLUSION: The synergistic and additive interactions make NSC-95397, emetine, and CGP-74514A hydrochloride potential candidates for incorporation into combination chemotherapy regimens and these drugs might be the suitable candidates for further clinical studies in patients with bronchial carcinoids and pancreatic endocrine tumors.
  • Larsson, Dhana E., et al. (författare)
  • Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines
  • 2006
  • Ingår i: Anticancer Research. - 0250-7005. ; 26:6B, s. 4125-4129
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to investigate drug sensitivity in neuroendocrine tumor cell lines. Materials and Methods: In vitro drug sensitivity screening was performed using the fluorometric microculture cytotoxicity assay in one human pancreatic carcinoid and two human bronchial carcinoid cell lines. In addition, a normal human retinal pigment epithelial cell line was used for comparison. A total of 18 drugs with different mechanisms of action were tested. Results: The most active agents were brefeldin A, emetine, bortezomib and idarubicin, having IC50 values < 1 μM in all four cell lines. In addition, the three tumor cell lines showed sensitivity for sanguinarine, Bay11-7085, mitoxantrone, doxorubicin, β-lapachone, NSC 95397 and CGP-74514A. Conclusion: The cell lines were sensitive for several drugs acting in different ways, covering a broad spectrum of mechanisms of action. Some of these compounds may possibly be used in clinical trials and show therapeutic effect in patients with neuroendocrine tumors.
  • Lewensohn, Rolf, et al. (författare)
  • p53 is involved in clearance of ionizing radiation-induced RAD51 foci in a human colon cancer cell line
  • 2006
  • Ingår i: Biochemical and Biophysical Research Communications - BBRC. - 0006-291X. ; 342:4, s. 1211-7
  • Tidskriftsartikel (refereegranskat)abstract
    • We have investigated p53-related differences in cellular response to DNA damaging agents, focusing on p53s effects on RAD51 protein level and sub-cellular localization post exposure to ionizing radiation. In a human colon cancer cell line, HCT116 and its isogenic p53-/- subcell line we show here p53-independent RAD51 foci formation but interestingly the resolution of RAD51 foci showed clear p53 dependence. In p53 wt cells, but not in p53-/- cells, RAD51 protein level decreased 48 h post irradiation and fluorescence immunostaining showed resolution of RAD51 foci and relocalization of RAD51 to nucleoli at time points corresponding to the decrease in RAD51 protein level. Both cell lines rejoined DNA double strand breaks efficiently with similar kinetics and p53 status did not influence sensitivity to DNA damaging agents. We suggest that p53 has a role in RAD51 clearance post DSB repair and that nucleoli might be sites of RAD51 protein degradation.
  • Lewensohn, Rolf, et al. (författare)
  • The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
  • 2007
  • Ingår i: Molecular Cancer Therapeutics. - 1535-7163. ; 6:9, s. 2409-2417
  • Tidskriftsartikel (refereegranskat)abstract
    • Neuroblastoma is the most common extracranial solid tumor of childhood. The activity of J1 (l-melphalanyl-p-l-fluorophenylalanine ethyl ester), an enzymatically activated melphalan prodrug, was evaluated in neuroblastoma models in vitro and in vivo. Seven neuroblastoma cell lines with various levels of drug resistance were screened for cytotoxicity of J1 alone or in combination with standard cytotoxic drugs, using a fluorometric cytotoxicity assay. J1 displayed high cytotoxic activity in vitro against all neuroblastoma cell lines, with IC50 values in the submicromolar range, significantly more potent than melphalan. The cytotoxicity of J1, but not melphalan, could be significantly inhibited by the aminopeptidase inhibitor bestatin. J1 induced caspase-3 cleavage and apoptotic morphology, had additive effects in combination with doxorubicin, cyclophosphamide, carboplatin, and vincristine, and synergistically killed otherwise drug-resistant cells when combined with etoposide. Athymic rats and mice carrying neuroblastoma xenografts [SH-SY5Y, SK-N-BE(2)] were treated with equimolar doses of melphalan, J1, or no drug, and effects on tumor growth and tissue morphology were analyzed. Tumor growth in vivo was significantly inhibited by J1 compared with untreated controls. Compared with melphalan, J1 more effectively inhibited the growth of mice with SH-SY5Y xenografts, was associated with higher caspase-3 activation, fewer proliferating tumor cells, and significantly decreased mean vascular density. In conclusion, the melphalan prodrug J1 is highly active in models of neuroblastoma in vitro and in vivo, encouraging further clinical development in this patient group.
  • Ahlin, Gustav, et al. (författare)
  • Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1
  • 2008
  • Ingår i: Journal of Medicinal Chemistry. - 0022-2623. ; 51:19, s. 5932-5942
  • Tidskriftsartikel (refereegranskat)abstract
    • The liver-specific organic cation transport protein (OCT1; SLC22A1) transports several cationic drugs including the antidiabetic drug metformin and the anticancer agents oxaliplatin and imatinib. In this study, we explored the chemical space of registered oral drugs with the aim of studying the inhibition pattern of OCT1 and of developing predictive computational models of OCT1 inhibition. In total, 191 structurally diverse compounds were examined in HEK293-OCT1 cells. The assay identified 47 novel inhibitors and confirmed 15 previously known inhibitors. The enrichment of OCT1 inhibitors was seen in several drug classes including antidepressants. High lipophilicity and a positive net charge were found to be the key physicochemical properties for OCT1 inhibition, whereas a high molecular dipole moment and many hydrogen bonds were negatively correlated to OCT1 inhibition. The data were used to generate OPLS-DA models for OCT1 inhibitors; the final model correctly predicted 82% of the inhibitors and 88% of the noninhibitors of the test set.
  • Andersen, Malin, et al. (författare)
  • Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells
  • 2007
  • Ingår i: Nucleic Acids Research. - 0305-1048. ; 35:5, s. e34
  • Tidskriftsartikel (refereegranskat)abstract
    • Using the relative expression levels of two SNP alleles of a gene in the same sample is an effective approach for identifying cis-acting regulatory SNPs (rSNPs). In the current study, we established a process for systematic screening for cis-acting rSNPs using experimental detection of AI as an initial approach. We selected 160 expressed candidate genes that are involved in cancer and anticancer drug resistance for analysis of AI in a panel of cell lines that represent different types of cancers and have been well characterized for their response patterns against anticancer drugs. Of these genes, 60 contained heterozygous SNPs in their coding regions, and 41 of the genes displayed imbalanced expression of the two cSNP alleles. Genes that displayed AI were subjected to bioinformatics-assisted identification of rSNPs that alter the strength of transcription factor binding. rSNPs in 15 genes were subjected to electrophoretic mobility shift assay, and in eight of these genes (APC, BCL2, CCND2, MLH1, PARP1, SLIT2, YES1, XRCC1) we identified differential protein binding from a nuclear extract between the SNP alleles. The screening process allowed us to zoom in from 160 candidate genes to eight genes that may contain functional rSNPs in their promoter regions.
Skapa referenser, mejla, bekava och länka
fritt online (8)
Typ av publikation
tidskriftsartikel (86)
konferensbidrag (13)
rapport (4)
bok (4)
bokkapitel (4)
samlingsverk (redaktörskap) (2)
visa fler...
annan publikation (1)
forskningsöversikt (1)
visa färre...
Typ av innehåll
refereegranskat (95)
övrigt vetenskapligt (17)
populärvet., debatt m.m. (3)
Larsson, Rolf, (85)
Nygren, Peter, (18)
Lindhagen, Elin (14)
Rickardson, Linda, (13)
Lövborg, Henrik (12)
Isaksson, Anders, (9)
visa fler...
Djurfeldt, Göran (9)
Åleskog, Anna, (9)
Jirström, Magnus (9)
Larsson, Nils-Goran, (9)
Gullbo, Joachim, (9)
Wibom, Rolf, (9)
Fryknäs, Mårten, (8)
Andersson, Göran (7)
Sanchez, Javier (7)
Wickström, Malin, (6)
Bohlin, Lars, (5)
Dhar, Sumeer (5)
Holmén, Hans, (5)
Bergquist, Jonas (4)
Larsson, Anders, (4)
Adolfsson, Rolf, (4)
Höglund, Martin, (4)
Manthorpe, Rolf (4)
Hedner, Erik (4)
Bredberg, Anders (4)
Larsson, Anne, (4)
Thorslund, Sara, (4)
Nikolajeff, Fredrik, (4)
Lewensohn, Rolf (4)
Sallmyr, Annahita (4)
Gundersen, Lise-Lott ... (4)
Charnock, Colin (4)
Ingvar, Martin, (3)
Linder, Stig, (3)
Gustafsson, Mats G, (3)
Hassan, Saadia, (3)
Öberg, Fredrik, (3)
Karlsson, Mats O, (3)
Hultenby, Kjell, (3)
Van Broeckhoven, Chr ... (3)
Nilsson, Bo, (3)
Korsgren, Olle, (3)
Larsson, Rolf G, (3)
Westerberg, Bo, (3)
Christensen, Kjeld (3)
Nyberg, Lars, 1966-, (3)
von Döbeln, Ulrika, (3)
Larsson, Åke (3)
Haglund, Caroline, (3)
visa färre...
Uppsala universitet (68)
Karolinska Institutet (29)
Lunds universitet (17)
Linnéuniversitetet (8)
Umeå universitet (8)
Linköpings universitet (6)
visa fler...
Luleå tekniska universitet (4)
Stockholms universitet (4)
Sveriges Lantbruksuniversitet (3)
Malmö högskola (2)
Kungliga Tekniska Högskolan (2)
Göteborgs universitet (1)
visa färre...
Engelska (103)
Svenska (7)
Odefinierat språk (5)
Ämne (HSV)
Medicin och hälsovetenskap (1)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy